Amgen confirms it is working on a version of Alexion's drug

Amgen developing Soliris biosimilar

By Gareth Macdonald contact

- Last updated on GMT


Related tags: Pharmacology, Food and drug administration

Amgen has started a trial of a biosimilar version of Alexion Pharmaceuticals’ Soliris (Eculizumab).

The study - which was posted on the Australia New Zealand Clinical Trial Registry in April​ – is comparing the pharmacokinetic profile of Amgen’s candidate ABP 959 with Alexion’s drug in healthy male subjects.

Soliris is a humanized monoclonal antibody that inhibits an immune system protein - Complement component 5 - that is associated with damaging inflammatory responses in a number of diseases. 

It is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).


Soliris is one of the most expensive medicines in the world.

According to the British national formulary ​it costs £3150 per 30 ml vial, excluding VAT.

NICE​, the organisation that decides which drugs and treatments are available on the NHS in Wales and England, estimates that Solris costs "£340,200 (initial and maintenance treatment) in the first year of treatment and about £327,600 for 1 year of treatment on the recommended maintenance dose.​"

One of nine

An Amgen spokeswoman confirmed the firm is working on a version of the drug.

"All that we can say at this time is that Amgen has nine biosimilars in development, including a biosimilar candidate to Soliris. We look forward to providing further updates at the appropriate time​."

Amgen is not the only firm working on a Soliris biosimilar.

According to a recent SEC filing​ Epirus Biopharmaceutical is also developing a version of the product called BOW080​.

On its website​ Boston-based Epirus states it expects to file the drug in 2020.

Related news

Show more

Related products

show more

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Single-Step Influenza and Dengue Virus Purification

Single-Step Influenza and Dengue Virus Purification

Bio-Rad Laboratories | 08-Oct-2018 | Application Note

CHT XT is the newest addition to the CHT family of media. It has been designed for superior physical robustness to ensure it can be used repeatedly over...

Downstream Purification of Large Biomolecules

Downstream Purification of Large Biomolecules

Bio-Rad Laboratories | 17-Sep-2018 | Research Study

Our newest strong anion exchange resin provides both high binding capacity and
high recovery, even at high flow rates. A rigid bead complete with...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Related suppliers

Follow us


View more